Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Novartis Pharmaceuticals
Scientific Title
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors